1. Home
  2. CCS vs ARQT Comparison

CCS vs ARQT Comparison

Compare CCS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCS
  • ARQT
  • Stock Information
  • Founded
  • CCS 2000
  • ARQT 2016
  • Country
  • CCS United States
  • ARQT United States
  • Employees
  • CCS 1873
  • ARQT N/A
  • Industry
  • CCS Homebuilding
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCS Consumer Discretionary
  • ARQT Health Care
  • Exchange
  • CCS Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • CCS 1.7B
  • ARQT 2.1B
  • IPO Year
  • CCS 2014
  • ARQT 2020
  • Fundamental
  • Price
  • CCS $56.79
  • ARQT $27.65
  • Analyst Decision
  • CCS Buy
  • ARQT Strong Buy
  • Analyst Count
  • CCS 4
  • ARQT 7
  • Target Price
  • CCS $80.75
  • ARQT $22.17
  • AVG Volume (30 Days)
  • CCS 336.2K
  • ARQT 3.1M
  • Earning Date
  • CCS 10-22-2025
  • ARQT 10-28-2025
  • Dividend Yield
  • CCS 2.04%
  • ARQT N/A
  • EPS Growth
  • CCS N/A
  • ARQT N/A
  • EPS
  • CCS 6.93
  • ARQT N/A
  • Revenue
  • CCS $4,157,669,000.00
  • ARQT $317,929,000.00
  • Revenue This Year
  • CCS N/A
  • ARQT $85.27
  • Revenue Next Year
  • CCS $8.74
  • ARQT $30.70
  • P/E Ratio
  • CCS $8.19
  • ARQT N/A
  • Revenue Growth
  • CCS N/A
  • ARQT 129.21
  • 52 Week Low
  • CCS $50.42
  • ARQT $8.90
  • 52 Week High
  • CCS $95.76
  • ARQT $27.92
  • Technical
  • Relative Strength Index (RSI)
  • CCS 37.21
  • ARQT 69.56
  • Support Level
  • CCS $58.88
  • ARQT $22.26
  • Resistance Level
  • CCS $60.76
  • ARQT $24.39
  • Average True Range (ATR)
  • CCS 1.66
  • ARQT 1.49
  • MACD
  • CCS -0.29
  • ARQT 0.11
  • Stochastic Oscillator
  • CCS 21.35
  • ARQT 91.70

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: